Abstract: The present invention relates to a method for the preparation of a solution of immunoglobulins based on an initial solution of immunoglobulins with a purity greater than or equal to 96% in the presence of a polyether or polymer of glycol, characterized in that it comprises the steps of: a) adding caprylic acid or salts of the same to the initial solution; b) adjusting the pH of the solution obtained in step a); c) incubating the solution obtained in step b) for the time and at a temperature necessary for the inactivation of enveloped viruses; d) performing a step of ultrafiltration/diafiltration on the solution obtained in step c).

Abstract: A method prepares a solution of human albumin by reducing dissolved oxygen in a solution of albumin until a concentration of oxygen equal to or less than 0.5 ppm is achieved. A solution of human albumin having a redox state closer to the redox state of the albumin present in human plasma can be achieved.

Abstract: A method of purification of non-enveloped or pseudo-enveloped virus produced in vitro uses a composition with at least one detergent. A method of purification can use multiple detergents, and a method of determining the presence and/or level of a non-enveloped or pseudo-enveloped virus in a sample includes treating with at least one detergent.

Abstract: Polybrene as an additive in cell culture medium is used in methods for the generation of high-titer hepatitis E virus stocks and assays for titration of hepatitis E virus. A cell culture medium containing polybrene is used for high-titer HEV generation, a method for determining the presence and/or the level of HEV in a sample, and an HEV titration assay using polybrene.

Abstract: An RFID tag is for arrangement on a bottle for blood-derived products. The bottle includes a main body, the upper end of which includes a neck. The bottle is hermetically sealed by a cap arranged in the upper portion of the neck. The upper portion of the cap includes at least two through-pipes and at least two stiffening ribs that are each connected to the pipes by one of the respective ends thereof. The RFID tag has at least two openings shaped to fit each of the through-pipes, respectively, of the cap such that said RFID tag is positioned on the upper surface of the cap and thus overcomes the obstacle of the through-pipes and the respective stiffening ribs.

Abstract: The apparatus has a containing body with a flat upper functional floor for containing receptacles of reagents, diluents and samples, as well as housings for gel cards and incubators for the same; a lower floor containing receptacles for washing liquids and the collection of waste and cards and for housing the fluid control and electronic control system; a series of longitudinal and transverse guides associated with the upper part of the apparatus, suitable for carrying in suspension the moving heads of the apparatus, the heads being movable on the transverse guides; two heads, respectively for perforation and pipetting and for the transport of gel cards; two centrifuges and a gel card reader; and a folding touch screen providing information and control.

Abstract: The invention describes a method for the automatic filling of containers for medication for intravenous administration in a machine for the automatic preparation of intravenous medication, the said containers comprising at least one fluid inlet connector closed by a cap that comprises an internal through conduit, said machine comprising injectors with spikes actuated by at least actuating means arranged in the said machine. The said method is characterized in that the said spike causes a piercing of one of the ends of said cap, allowing the direct injection of said component into said container.

Abstract: Described herein are methods for purifying recombinant, cell culture derived alpha1-protease inhibitor and removing a colored species that co-purifies with the recA1PI protein. Also described are methods for reducing the iron in cell culture derived alpha1-protease inhibitor.

Abstract: A machine for preparing substances for intravenous application includes: an initial container reception zone, a final container reception zone and a substance transfer circuit which includes a set of substance extraction devices, each of which is connected to a flexible tube connected to a device for introducing a substance into the final container by means of a peristaltic pump. The initial container reception zone and the vector of extraction devices are capable of relative movement along a horizontal axis and/or the final container reception zone and the vector of introduction devices are capable of relative movement along a horizontal axis.

Abstract: A robotized syringe actuator has a holding clamp for holding the peripheral flange of the opening of the tube or the flange at the end of the syringe plunger, by applying simultaneous pressure to both faces of the tube flange or of the syringe plunger flange. The actuator has a holder for the syringe cylinder which has a housing for receiving the syringe tube.

Abstract: A hermetically-sealed plastics container for blood derivative products is provided. The container may have an internal surface and an external surface, characterized in that it comprises an RFID inlay between the internal surface and the external surface.

Abstract: A method identifies atypical antibodies in blood or blood product manufacturing processes that may produce false positives in quality control testing on intermediate or final products.

Abstract: A process for filling pharmaceutical product containers in a container filling machine with the stages of: filling the container with the corresponding pharmaceutical substance through filling means in a filling station of the filling machine, weighing the filled container in a filled container weighing station to confirm that the quantity of pharmaceutical substance with which the container has been filled lies within the desired range, in which when the quantity of pharmaceutical substance with which the container has been filled lies outside the desired range the filling means are moved to the filled container weighing station and the container is topped up with a quantity such that the total substance placed in the container in the two stages lies within the desired range.

Abstract: A composition, which relates to the field of the clinical analysis of blood, comprises human plasma, buffered isotonic solution and ferulic acid. The composition can be used as an abnormal coagulation control in haemostasis, coagulation and fibrinolysis assays. Ferulic acid can be used in the preparation of abnormal control plasma in haemostasis assays.

Abstract: Described herein are methods for purifying recombinant, cell culture derived alpha1-protease inhibitor and removing a colored species that co-purifies with the recA1PI protein. Also described are methods for reducing the iron in cell culture derived alpha1-protease inhibitor.

Abstract: Described herein are devices and methods for thawing frozen biological products efficiently without harming the products.

Abstract: An alpha1-proteinase inhibitor delays the onset or progression of pulmonary exacerbations. In addition, methods delay the onset or diminish the progression of pulmonary exacerbations by the administration of inhaled alpha1-proteinase inhibitor.

Abstract: The stable thrombin composition comprises purified thrombin, human albumin and a neutral salt, the resulting product being stable when stored as a lyophilisate or frozen and is adjusted to a nominal strength of 500 IU of thrombin or more per ml of solution, the human albumin being in a concentration of over 0.05% (w/v) and preferably between 0.1% (w/v) and 1% (w/v).

Abstract: Described herein are methods for purifying recombinant, cell culture derived alpha1-protease inhibitor and removing a colored species that co-purifies with the recA1PI protein. Also described are methods for reducing the iron in cell culture derived alpha1-protease inhibitor.